Services on Demand
- Cited by SciELO
- Access statistics
Revista da Associação Médica Brasileira
Print version ISSN 0104-4230
On-line version ISSN 1806-9282
POLI NETO, Omero Benedicto et al. Febrile neutropenia in patients with breast cancer submitted to chemotherapy: a 12 year experience. Rev. Assoc. Med. Bras. [online]. 2004, vol.50, n.4, pp.363-366. ISSN 0104-4230. http://dx.doi.org/10.1590/S0104-42302004000400023.
PURPOSE: To identify the characteristis of patients with breast cancer who developed febrile neutropenia and to establish risk factors for its incidence and parameters for an unfavorable evolution. PATIENTS AND METHODS: A case-control study was performed and included 65 patients: 13 patients presented febrile neutropenia and four controls per case matched by: date and number of previous chemotherapy cycles, drugs and doses used. The clinical and laboratory data were obtained from medical records. We utilized the odds ratio (OR) and the 95% confidence interval (CI) to estimate the significance of risk factors. RESULTS: We identified two risk factors associated to occurrence of febrile neutropenia: use of chemotherapy within the first 24 hours post surgery (OR: 159.9 95% CI: 9.5 to 2699), and the concomitant use of chemotherapy and breast radiotherapy (OR: 108.3 95%CI: 4.9 to 2391). We did not observe a significant difference between cases and controls regarding age, body mass index, neutrophils and monocytes count prior to chemotherapy. Three patients died (23.1%), two of them were more than 60 years old, had no comorbidities, had received the first CMF within the first post surgery day and had surgical site infection. CONCLUSIONS: The main risk factors associated with febrile neutropenia in patients with breast cancer were: chemotherapy within the first 24 hours post surgery, and concomitant chemotherapy and breast radiotherapy. As such, our study shows that these situations must be avoided.
Keywords : Febrile neutropenia; Breast cancer; Chemotherapy; Radiotherapy.